NCT01860417

Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)

Treatment of Lumbar Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV*) *MSV: Bone Marrow Mesenchymal Stromal Cells Expanded Using the Valladolid IBGM Procedure

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Red de Terapia Celular · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

In this study we want to evaluate the clinical use of allogenic mesenchymal stem cells (MSC), obtained from bone marrow of healthy donors, for treatment of Degenerative Disc Disease (DDD). The trial is based in previous results with autologous MSC (Orozco et al., Transplantation 92: 822-828; 2011). Here we propose a phase I-II trial, prospective, randomized, blinded, and controlled for the treatment DDD using MSV, a Good Manufacturing Practice (GMP)-compliant expanded bone marrow MSC (MSV, Investigational medicinal product Num. 10-134). The assay consists of two arms with 12 patients each one. Patients in the experimental arm will be given a single intra-discal transplantation of MSV (25 millions in 2 ml). Control patients will be infiltrated in the paravertebral muscles close to the lesion with 2 ml of 1% mepivacain. We shall follow the evolution of pain, disability and quality of life as well as disc fluid content by Magnetic Resonance Imaging (T2-calibrated).

Conditions

• Degenerative Disc Disease
• Intervertebral Disc Disease
• Low Back Pain

Interventions

Type	Name	Description
BIOLOGICAL	Allogenic Mesenchymal Stromal Cells
DRUG	Mepivacaine

Timeline

• Start date: 2013-06-21
• Primary completion: 2015-12-15
• Completion: 2015-12-15
• First posted: 2013-05-22
• Last updated: 2024-04-29
• Results posted: 2024-04-29

Locations

2 sites across 1 country: Spain